ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019).
Curr Drug Discov Technol
; 18(6): e130921189567, 2021.
Article
in English
| MEDLINE | ID: covidwho-999946
ABSTRACT
A novel coronavirus termed nCoV-2019 that caused an epidemic of acute respiratory syndrome in humans was first detected in Wuhan, China, in December 2019. nCoV-2019 resulted in thousands of cases of lethal disease all around the world. Unfortunately, there is no specific treatment yet, so a better understanding of the pathobiology of the disease can be helpful. The renin-angiotensin system and its products have several important physiological actions. On the other hand, this system is involved in the pathogenesis of various diseases. In this context, this review article will briefly discuss insights for understanding the role of the angiotensin-converting enzyme 2 (ACE2) receptor as a potentially attractive target for the nCoV-2019-induced acute respiratory syndrome.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Receptors, Virus
/
Renin-Angiotensin System
/
Virus Internalization
/
Angiotensin-Converting Enzyme 2
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Lung
Limits:
Animals
/
Humans
Language:
English
Journal:
Curr Drug Discov Technol
Journal subject:
Pharmacology
Year:
2021
Document Type:
Article
Affiliation country:
1570163817999201228215911
Similar
MEDLINE
...
LILACS
LIS